Zobrazeno 1 - 10
of 302
pro vyhledávání: '"Andrea Wang-Gillam"'
Autor:
Xiuli Zhang, S. Peter Goedegebuure, Michael Y. Chen, Rashmi Mishra, Felicia Zhang, Yik Yeung Yu, Kartik Singhal, Lijin Li, Feng Gao, Nancy B. Myers, Tammi Vickery, Jasreet Hundal, Michael D. McLellan, Mark A. Sturmoski, Samuel W. Kim, Ina Chen, Jesse T. Davidson, Narendra V. Sankpal, Stephanie Myles, Rama Suresh, Cynthia X. Ma, Ademuyiwa Foluso, Andrea Wang-Gillam, Sherri Davies, Ian S. Hagemann, Elaine R. Mardis, Obi Griffith, Malachi Griffith, Christopher A. Miller, Ted H. Hansen, Timothy P. Fleming, Robert D. Schreiber, William E. Gillanders
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both HLA class I and II
Externí odkaz:
https://doaj.org/article/361f87535f3347da8e2cfda87d75ab59
Autor:
Ashenafi Bulle, Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra, Vikas Somani, Iftikhar Ali Khawar, Hung-Po Chen, Paarth B. Dodhiawala, Lin Li, Yutong Geng, Chia-Kuei Mo, Jay Mahsl, Li Ding, Ramaswamy Govindan, Sherri Davies, Jacqueline Mudd, William G. Hawkins, Ryan C. Fields, David G. DeNardo, Deborah Knoerzer, Jason M. Held, Patrick M. Grierson, Andrea Wang-Gillam, Marianna B. Ruzinova, Kian-Huat Lim
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy. Util
Externí odkaz:
https://doaj.org/article/fb6737dcacf54c9e884795a4aec86099
Autor:
Afsaneh Barzi, Caroline M. Weipert, Carin R. Espenschied, Victoria M. Raymond, Andrea Wang-Gillam, Mohammad Amin Nezami, Eva J. Gordon, Daruka Mahadevan, Kabir Mody
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeDespite accumulating data regarding the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), olaparib is the only biomarker-driven FDA-approved targeted therapy with a PDAC-specific approval. Treating ERBB2(HER2)-amplified PDAC with a
Externí odkaz:
https://doaj.org/article/e7677069cab2423eb1241b17d63bdd06
Autor:
Kevin Conlon, Robert Wesolowski, Douglas G McNeel, John A Thompson, Rom Leidner, Andrea Wang-Gillam, Sumati Gupta, Nancy Lewis, George N Pavlakis, Lang Ho Lee, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Jessica A O’Keeffe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombin
Externí odkaz:
https://doaj.org/article/2886323ab834455e8737872e76203efc
Autor:
Marcus S. Noel, Semmie Kim, Marion L. Hartley, Steve Wong, Vincent J. Picozzi, Harry Staszewski, Dae Won Kim, Jan M. Van Tornout, Philip Agop Philip, Vincent Chung, Allyson J. Ocean, Andrea Wang‐Gillam
Publikováno v:
Cancer Medicine, Vol 11, Iss 22, Pp 4169-4181 (2022)
Abstract Background This trial explores SM‐88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) Methods Forty‐nine patients were randomized to daily 460 or 920 mg oral SM‐88
Externí odkaz:
https://doaj.org/article/566d5c8953714e0c95e07051f157b1d7
Autor:
Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe, Fernanda Martins Rodrigues, Nadezhda V. Terekhanova, Yize Li, Kian-Huat Lim, Andrea Wang-Gillam, Brian A. Van Tine, Cynthia X. Ma, Rebecca Aft, Katherine C. Fuh, Julie K. Schwarz, Jose P. Zevallos, Sidharth V. Puram, John F. Dipersio, The NCI PDXNet Consortium, Brandi Davis-Dusenbery, Matthew J. Ellis, Michael T. Lewis, Michael A. Davies, Meenhard Herlyn, Bingliang Fang, Jack A. Roth, Alana L. Welm, Bryan E. Welm, Funda Meric-Bernstam, Feng Chen, Ryan C. Fields, Shunqiang Li, Ramaswamy Govindan, James H. Doroshow, Jeffrey A. Moscow, Yvonne A. Evrard, Jeffrey H. Chuang, Benjamin J. Raphael, Li Ding
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-20 (2021)
Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and the
Externí odkaz:
https://doaj.org/article/e6286532f9bc487a87943a142621d7a3
Autor:
Yao Lu, Dao Xin, Lulu Guan, Mengli Xu, Yalan Yang, Yu Chen, Yuanyuan Yang, Andrea Wang-Gillam, Li Wang, Shanggang Zong, Feng Wang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeTo characterize the mechanism by which metformin inhibits PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and to evaluate the effect of metformin on the antitumor immune response.MethodsThe Cancer Genome Atlas (TCGA) database was
Externí odkaz:
https://doaj.org/article/c861b8c7f13c4c35a4f101a9ac29c246
Autor:
Kevin Conlon, Douglas G McNeel, John A Thompson, Sema Kurtulus, Rom Leidner, Thomas A Waldmann, Andrea Wang-Gillam, William D Figg, Sumati Gupta, Cristina Bergamaschi, George N Pavlakis, Antonio Valentin, Barbara K Felber, Mario Roederer, Dionysios C Watson, Cody J Peer, E Lake Potter, Nehal S Parikh, Debby Long, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/05cda4cb9225447c85e4cdf802228026
Autor:
Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent Picozzi, Vaibhav Sahai, Eileen M. O'Reilly
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Abstract Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and Methods Aphase 2, randomized, placebo‐cont
Externí odkaz:
https://doaj.org/article/65d331d0de7c4b2799fe21f23c85e265
Autor:
Comron Hassanzadeh, MD, MPH, Soumon Rudra, MD, Ani Bommireddy, BA, William G. Hawkins, MD, Andrea Wang-Gillam, MD, PhD, Ryan C. Fields, MD, Bin Cai, PhD, Justin Park, PhD, Olga Green, PhD, Michael Roach, MD, Lauren Henke, MD, Hyun Kim, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 1, Pp 100506- (2021)
Purpose: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited
Externí odkaz:
https://doaj.org/article/d8503a078e544338b1bba5cb23c0ce94